tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks 50 IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsMost Visited Websites
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA

RGNX Stock Latest News

RegenXBio’s Strengthened Financial Position and Growth Prospects Drive Buy Rating
RatingsRegenXBio’s Strengthened Financial Position and Growth Prospects Drive Buy Rating
15h ago
RGNX
RegenXBio Secures $250M Royalty Monetization Deal
PremiumCompany Announcements
RegenXBio Secures $250M Royalty Monetization Deal
20h ago
8K
RGNX
Regenxbio signs strategic royalty monetization agreement for up to $250M
PremiumThe Fly
Regenxbio signs strategic royalty monetization agreement for up to $250M
21h ago
RGNX
REGENXBIO’s Earnings Call Highlights Strong Start to Fiscal Year
PremiumCompany Announcements
REGENXBIO’s Earnings Call Highlights Strong Start to Fiscal Year
5d ago
RGNX
NS Pharma announces FDA accepted BLA submission of Regenxbio for RGX-121
PremiumThe Fly
NS Pharma announces FDA accepted BLA submission of Regenxbio for RGX-121
6d ago
RGNX
RegenXBio’s Promising Pipeline and Financial Stability Earns Buy Rating
PremiumRatingsRegenXBio’s Promising Pipeline and Financial Stability Earns Buy Rating
6d ago
RGNX
Promising Pipeline and Strong Financials Support Buy Rating for RegenXBio
Premium
Ratings
Promising Pipeline and Strong Financials Support Buy Rating for RegenXBio
7d ago
RGNX
Regenxbio’s BLA for RGX-121 in Hunter syndrome accepted by FDA
Premium
The Fly
Regenxbio’s BLA for RGX-121 in Hunter syndrome accepted by FDA
7d ago
RGNX
Optimistic Buy Rating for RegenXBio Amidst Promising Gene Therapy Developments and Financial Prospects
PremiumRatings
Optimistic Buy Rating for RegenXBio Amidst Promising Gene Therapy Developments and Financial Prospects
7d ago
RGNX
REGENXBIO Reports Strong Q1 2025 Financial Results
PremiumCompany Announcements
REGENXBIO Reports Strong Q1 2025 Financial Results
8d ago
RGNX
Regenxbio reports Q1 EPS 12c vs. ($1.38) last year
PremiumThe Fly
Regenxbio reports Q1 EPS 12c vs. ($1.38) last year
8d ago
RGNX
Controversial doctor Vinay Prasad named CBER director, STAT reports
PremiumThe Fly
Controversial doctor Vinay Prasad named CBER director, STAT reports
14d ago
DYN
RNA
RGNX Earnings this Week: How Will it Perform?
PremiumPre-EarningsRGNX Earnings this Week: How Will it Perform?
22d ago
RGNX
RBC sees Makary interview as potentially positive for biotech stocks
Premium
The Fly
RBC sees Makary interview as potentially positive for biotech stocks
29d ago
DYN
RNA
Biotech stocks slide as Marks resignation seen being negative for sector
Premium
The Fly
Biotech stocks slide as Marks resignation seen being negative for sector
2M ago
DYN
MGX
Marks resignation ‘not good’ for biotech sector, says RBC
PremiumThe Fly
Marks resignation ‘not good’ for biotech sector, says RBC
2M ago
DYN
RNA
Biotech Alert: Searches spiking for these stocks today
PremiumThe Fly
Biotech Alert: Searches spiking for these stocks today
2M ago
INO
ARCT
RegenXBio Positioned Favorably Amid Competitor Safety Concerns, Justifying Buy Rating
PremiumRatings
RegenXBio Positioned Favorably Amid Competitor Safety Concerns, Justifying Buy Rating
2M ago
RGNX
Optimistic Buy Rating for RegenXBio Driven by Promising RGX-202 Developments in DMD Treatment
PremiumRatings
Optimistic Buy Rating for RegenXBio Driven by Promising RGX-202 Developments in DMD Treatment
2M ago
RGNX
Regenxbio reports data from Phase I/II portion of the Affinity Duchenne trial
PremiumThe FlyRegenxbio reports data from Phase I/II portion of the Affinity Duchenne trial
2M ago
RGNX
RegenXBio’s RGX-202: A Safe and Promising Gene Therapy with Best-in-Class Potential
Premium
Ratings
RegenXBio’s RGX-202: A Safe and Promising Gene Therapy with Best-in-Class Potential
2M ago
RGNX
RegenXBio’s Promising Market Position and RGX-202’s Differentiated Safety Drive Buy Rating
Premium
Ratings
RegenXBio’s Promising Market Position and RGX-202’s Differentiated Safety Drive Buy Rating
2M ago
RGNX

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >